ATAI Life Sciences N.V. Stock News

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced the completion of a $149.5 million public offering of approximately 27 million common shares, including the full exercise of underwriters' option to purchase an additional 3.6 million shares at $5.48 per share. The financing included participation from both new and existing investors, such as Janus Henderson Investors, Foresite Capital, Deep T...

Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003

ATAI's main value driver is BPL-003. This candidate showed rapid and durable TRD benefits in its Phase 2b trials. BPL-003's 8 mg dose seemed to be ideal, which is why ATAI is going ahead with a Phase 3 with this dosing by Q2 2026. ATAI's broader pipeline includes VLS-01 DMT buccal film, EMP-01 R-MDMA for SAD, and other early-stage non-hallucinogenic 5-HT2A candidates.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has priced its registered underwritten offering of 23,725,000 company common shares at $5.48 per share, with expectations of raising about $130 million.  The clinical-stage biopharmaceutical company said it intends to use the net proceeds of the offering, together with existing cash, cash equivalents and short-term investments, to adva...

Atai Life Sciences (ATAI -7.63%), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer group.

NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of $5.48 per share. atai has granted the underwriters a 30-day opti...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) and Beckley Psytech announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to BPL-003 (mebufotenin benzoate) nasal spray for adult patients with treatment-resistant depression (TRD). The FDA's Breakthrough Therapy designation is intended to accelerate the development of drugs for serious or life-threatening...

NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of its common shares. atai expects to grant the underwriters a 30-day option to purchase addi...